Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
aging
Podcast
BioAge CEO talks NLRP3 and ‘pipeline in a pill’ ambitions
BioAge CEO Kristen Fortney sits down with Fierce Editor-in-Chief Ayla Ellison to discuss aging biology, inflammation and NLRP3 drugs.
Ayla Ellison
May 22, 2026 10:00am
BioAge CEO's big plans for 'multi-disease impact' of NLRP3 drug
May 14, 2026 11:00am
ARPA-H designates up to $144M for anti-aging medical research
Feb 25, 2026 11:55am
Chugai inks $250M deal for Gero’s age-related disease targets
Jul 7, 2025 3:00am
NewLimit raises $130M to push liver mRNA med into clinic
May 6, 2025 11:00am
BioAge secures Novartis deal worth up to $550M biobucks
Dec 18, 2024 10:44am
